Prices delayed by at least 15 minutes | Print


MannKind Corp (MNKD)

Common Shares
Sell: $4.1|Buy: $4.15|Change: 0.05 (1.23%)

Open 

$4.09


Previous close 

$4.05


Trade high 

$4.145


Volume 

2,453,484


Year high 

$5.75


Year low 

$3.17


Dividend yield 

-


Market capitalisation 

$1.11 bn


P/E ratio 

-


ISIN 

US56400P7069


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 17/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
MannKind Corp+ 1.23
More...

Company profile

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.